The anti-hepatitis B virus activity of boehmeria nivea extract in HBV-viremia SCID mice

Evidence-based Complementary and Alternative Medicine

Volumn 7, Issue 2, 2010, Pages 189-195

  Chang, Jia Ming ^a   Huang, Kai Ling ^b   Yuan, Thomas Ta Tung ^a   Lai, Yiu Kay ^b,c   Hung, Le Mei ^a  

^a DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c DA YEH UNIVERSITY   (Taiwan)

Author keywords

Folk medicine; HBsAg; HBV DNA; NK cells; SCID

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BOEHMERIA NIVEA EXTRACT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PLANT EXTRACT; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BOEHMERIA NIVEA; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; HEPATITIS B; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEDICINAL PLANT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; VIREMIA;

EID: 77952139225     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem180     Document Type: Article

References (31)

1. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-350
2. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987;56:651-693
3. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005;118:1413.
4. Mailliard ME, Gollan JL. Emerging therapeutics for chronic hepatitis B. Annu Rev Med 2006;57:155-166
5. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507
6. Lee SK, Wong CK, Poon PM, Ip PS, Che CT, Fung KP, et al. In vitro immunomodulatory activities of a newly concocted traditional Chinese medicine formula: VI-28. Phytother Res 2006;20:883-888
7. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001;4:118-128
8. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
9. Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat 2001;8:358-366 (Pubitemid 34205889)
10. Kang EH, Kown TY, Oh GT, Park WF, Park SI, Park SK, et al. The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res 2006;72:100-106
11. Li H, Zhou C, Zhou L, Chen Z, Yang L, Bai H, et al. In vitro antiviral activity of three enantiomeric sesquiterpene lactones from Senecio species against hepatitis B virus. Antivir Chem Chemother 2005;16:277-282
12. Chang JS, Liu HW, Wang KC, Chen MC, Chiang LC, Hua YC, et al. Ethanol extract of Polygonum cuspidatum inhibits hepatitis B virus in a stable HBV-producing cell line. Antiviral Res 2005;66:29-34.
13. Huang KL, Lai YK, Lin CC, Chang JM. Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells. World J Gastroenterol 2006;12:5721-5725
14. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25 (Suppl 1): 9-19.
15. Guha C, Mohan S, Roy-Chowdhury N, Roy-Chowdhury J. Cell culture and animal models of viral hepatitis. Part I: hepatitis B. Lab Anim 2004;33:37-46.
16. Prince AM, Brotman B. Perspectives on hepatitis B studies with chimpanzees. Ilar J 2001;42:85-88
17. Takahashi H, Fujimoto J, Hanada S, Isselbacher KJ. Acute hepatitis in rats expressing human hepatitis B virus transgenes. Proc Natl Acad Sci USA 1995;92:1470-1474
18. Zhai WR, Vajta G, Acs G, Paronetto F. A nude mouse model for the in vivo production of hepatitis B virus. Gastroenterology 1990;98:470-477
19. Sato H, Goto W, Yamamura J, Kurokawa M, Kageyama S, Takahara T, et al. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 1996;30:171-177
20. Dandri M, Volz TK, Lutgehetmann M, Petersen J. Animal models for the study of HBV replication and its variants. J Clin Virol 2005;34 (Suppl 1): S54-62.
21. Condreay LD, Jansen RW, Powdrill TF, Johnson LC, Selleseth DW, Paff MT, et al. Evaluation of the potent antihepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrob Agents Chemother 1994;38:616-619
22. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229-234
23. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007;81:100-107
24. Morrey JD, Bailey KW, Korba BE, Sidwell RW. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Antiviral Res 1999;42:97-108.
25. Morrey JD, Korba BE, Sidwell RW. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir Ther 1998;3:59-68.
26. Jilbert AR, Botten JA, Miller DS, Bertram EM, Hall PM, Kotlarski J, et al. Characterization of age-and dose-related outcomes of duck hepatitis B virus infection. Virology 1998;244:273-282
27. Liu N, Zhu B, Huang Z, Zhu Y, Chen Q, Guo X, et al. [The inhibitive effects of the ethanol extract from Radix et Rhizoma Rhei on the secretion of HBsAg and HBeAg]. Zhong Yao Cai 2004;27:419-421
28. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-1129
29. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-1319
30. Sun Y, Chen HY, Xin SJ. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2.2.15 cell lines. Hepatobiliary Pancreat Dis Int 2004;3:230-234
31. Sjolin H, Tomasello E, Mousavi-Jazi M, Bartolazzi A, Karre K, Vivier E, et al. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J Exp Med 2002;195:825-834